{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T12:39:21Z","timestamp":1770554361788,"version":"3.49.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background. \u2003Limited data exist on the safety of the measles, mumps, and rubella (MMR) vaccine in adults. We reviewed reports of adverse events (AEs) to the Vaccine Adverse Event Reporting System (VAERS) to assess safety in this previously understudied group.<\/jats:p>\n               <jats:p>Methods. \u2003VAERS is the national spontaneous vaccine safety surveillance system coadministered by the Centers for Disease Control and Prevention and the US Food and Drug Administration. We searched the VAERS database for US reports of adults aged \u226519 years who received the MMR vaccine from 1 January 2003 to 31 July 2013. We clinically reviewed reports and available medical records for serious AEs, pregnancy reports, and reports for selected prespecified outcomes.<\/jats:p>\n               <jats:p>Results. \u2003During this period, VAERS received 3175 US reports after MMR vaccine in adults. Of these, 168 (5%) were classified as serious, including 7 reports of death. Females accounted for 77% of reports. The most common signs and symptoms for all reports were pyrexia (19%), rash (17%), pain (13%), and arthralgia (13%). We did not detect any new safety findings in empirical Bayesian data mining. We identified 131 reports of MMR vaccine administered to a pregnant woman; the majority of these vaccinations were in the first trimester and in 83 (62%), no AE was reported.<\/jats:p>\n               <jats:p>Conclusions. \u2003In our review of VAERS data, we did not detect any new or unexpected safety concerns for MMR vaccination in adults. We identified reports of pregnant women exposed to MMR, which is a group in whom the vaccine is contraindicated, suggesting the need for continued provider education on vaccine recommendations and screening.<\/jats:p>","DOI":"10.1093\/cid\/civ061","type":"journal-article","created":{"date-parts":[[2015,1,31]],"date-time":"2015-01-31T05:58:01Z","timestamp":1422683881000},"page":"e58-e65","source":"Crossref","is-referenced-by-count":36,"title":["Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003\u20132013"],"prefix":"10.1093","volume":"60","author":[{"given":"Lakshmi","family":"Sukumaran","sequence":"first","affiliation":[{"name":"Centers for Disease Control and Prevention 1 Immunization Safety Office, Division of Healthcare Quality Promotion ,"},{"name":"Emory University School of Medicine, Atlanta, Georgia 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention 1 Immunization Safety Office, Division of Healthcare Quality Promotion ,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention 1 Immunization Safety Office, Division of Healthcare Quality Promotion ,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige W.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention 1 Immunization Safety Office, Division of Healthcare Quality Promotion ,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott K.","family":"Winiecki","sequence":"additional","affiliation":[{"name":"US Food and Drug Administration, Silver Spring, Maryland 3 Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research ,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom T.","family":"Shimabukuro","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention 1 Immunization Safety Office, Division of Healthcare Quality Promotion ,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,1,30]]},"reference":[{"key":"2024111411392579700_CIV061C1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1542\/peds.2013-3965","article-title":"Recommended childhood and adolescent immunization schedule\u2014United States, 2014","volume":"133","author":"Committee on Infectious Diseases, American Academy of Pediatrics","year":"2014","journal-title":"Pediatrics"},{"key":"2024111411392579700_CIV061C2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-158-3-201302050-00584","article-title":"Recommended adult immunization schedule: United States, 2013","volume":"158","author":"Advisory Committee on Immunization Practices","year":"2013","journal-title":"Ann Intern Med"},{"issue":"RR-04","key":"2024111411392579700_CIV061C3","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"2024111411392579700_CIV061C4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2010-0665","article-title":"Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics"},{"key":"2024111411392579700_CIV061C5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.292.3.351","article-title":"MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis","volume":"292","author":"Vestergaard","year":"2004","journal-title":"JAMA"},{"key":"2024111411392579700_CIV061C6","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1542\/peds.2007-1578","article-title":"Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children","volume":"121","author":"France","year":"2008","journal-title":"Pediatrics"},{"key":"2024111411392579700_CIV061C7","first-page":"976","article-title":"Nationwide campaign for vaccination of adults against rubella and measles\u2014Costa Rica, 2001","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024111411392579700_CIV061C8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0264-410X(91)90053-9","article-title":"Adverse events following measles-mumps-rubella and measles vaccinations in college students","volume":"9","author":"Chen","year":"1991","journal-title":"Vaccine"},{"key":"2024111411392579700_CIV061C9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1515\/IJAMH.2006.18.4.615","article-title":"Outbreak of measles in medical students and determination of immune status to measles-mumps-rubella viruses","volume":"18","author":"Yalcin","year":"2006","journal-title":"Int J Adolesc Med Health"},{"key":"2024111411392579700_CIV061C10","first-page":"496","article-title":"Measles\u2014United States, January 1-May 23, 2014","volume":"63","author":"Gastanaduy","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024111411392579700_CIV061C11","doi-asserted-by":"crossref","first-page":"pii:20395","DOI":"10.2807\/ese.18.06.20395-en","article-title":"Large measles outbreak in Geneva, Switzerland, January to August 2011: descriptive epidemiology and demonstration of quarantine effectiveness","volume":"18","author":"Delaporte","year":"2013","journal-title":"Euro Surveill"},{"key":"2024111411392579700_CIV061C12","article-title":"Surveillance report: measles and rubella monitoring","author":"European Centre for Disease Prevention and Control","year":"2013"},{"key":"2024111411392579700_CIV061C13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"2024111411392579700_CIV061C14","article-title":"Vaccine Adverse Event Reporting System (VAERS) form","author":"US Department of Health and Human Services"},{"key":"2024111411392579700_CIV061C15","article-title":"Medical dictionary for regulatory activities (MedDRA)","author":"International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)"},{"key":"2024111411392579700_CIV061C16","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1016\/j.vaccine.2010.09.021","article-title":"Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009\u2013January 31, 2010","volume":"28","author":"Vellozzi","year":"2010","journal-title":"Vaccine"},{"key":"2024111411392579700_CIV061C17","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"2024111411392579700_CIV061C18","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1016\/j.vaccine.2007.04.060","article-title":"Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Sejvar","year":"2007","journal-title":"Vaccine"},{"key":"2024111411392579700_CIV061C19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"2024111411392579700_CIV061C20","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1016\/j.vaccine.2007.02.067","article-title":"Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Wise","year":"2007","journal-title":"Vaccine"},{"key":"2024111411392579700_CIV061C21","doi-asserted-by":"crossref","first-page":"473 e1","DOI":"10.1016\/j.ajog.2011.06.047","article-title":"Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System","volume":"205","author":"Moro","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"2024111411392579700_CIV061C22","volume-title":"Williams obstetrics","author":"Cunningham","year":"2010","edition":"23rd ed"},{"key":"2024111411392579700_CIV061C23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"key":"2024111411392579700_CIV061C24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the USFDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"2024111411392579700_CIV061C25","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40264-013-0051-9","article-title":"Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010\u20132011 seasonal influenza virus vaccine","volume":"36","author":"Martin","year":"2013","journal-title":"Drug Saf"},{"key":"2024111411392579700_CIV061C26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"2024111411392579700_CIV061C27","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1542\/peds.100.5.767","article-title":"MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team","volume":"100","author":"Davis","year":"1997","journal-title":"Pediatrics"},{"key":"2024111411392579700_CIV061C28","article-title":"Status report on progress towards measles and rubella elimination","author":"SAGE Working Group on Measles and Rubella"},{"key":"2024111411392579700_CIV061C29","author":"Centers for Disease Control and Prevention. Measles Cases and Outbreaks"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/60\/10\/e58\/16787374\/civ061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/60\/10\/e58\/16787374\/civ061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:46:12Z","timestamp":1731584772000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/60\/10\/e58\/338042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,30]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,1,30]]},"published-print":{"date-parts":[[2015,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/civ061","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,5,15]]},"published":{"date-parts":[[2015,1,30]]}}}